Could a cold virus drug prevent COPD Flare-Ups?
NCT ID NCT06149494
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 33 times
Summary
This study tested an investigational drug called vapendavir in 52 adults with COPD (a chronic lung disease). The goal was to see if vapendavir could reduce lower respiratory symptoms like cough, wheezing, and shortness of breath after they were exposed to a common cold virus (rhinovirus). Participants were monitored for six weeks. The drug is not yet approved and aims to control disease flare-ups, not cure COPD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU)
London, W2 1NY, United Kingdom
Conditions
Explore the condition pages connected to this study.